

# Novel immunotherapeutic, TG1050, shows early signs of potential for chronic hepatitis B cure

April 23 2015

---

A novel immunotherapeutic in early development for chronic hepatitis B (CHB), TG1050, has been shown to reach the clinical goals that are considered to be the hallmarks of a cure for CHB, according to results revealed today at The International Liver Congress 2015.

The hallmarks of a CHB cure are:

- Elimination of HBsAg - the surface antigen of the hepatitis B virus, and
- HBsAg seroconversion - which occurs when a specific antibody becomes detectable in the blood and the corresponding antigen becomes undetectable, in this case HBsAg

In the study, decrease of HBsAg and HBsAg seroconversion was achieved in 30% of TG1050-injected mice.

Earlier studies have proven that TG1050 is able to induce a robust, multi-specific and long-lasting immune response against the hepatitis B virus. These latest results, which show that TG1050 is able to decrease HBsAg and lead to anti-HBsAg seroconversion in HBV persistent mouse models, support the move to a first-in-man study and the start of clinical development.

Provided by European Association for the Study of the Liver

Citation: Novel immunotherapeutic, TG1050, shows early signs of potential for chronic hepatitis B cure (2015, April 23) retrieved 26 April 2024 from

<https://medicalxpress.com/news/2015-04-immunotherapeutic-tg1050-early-potential-chronic.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.